BAN2401 Slows Cognitive Decline in Alzheimer Disease
BAN2401 produced a dose-dependent substantial reduction in brain amyloid plaque at the highest dose, resulting in subjects converting to amyloid negative.
Lynn Kramer, MD: BAN2401 Phase IIb Clinical Study Results
This is the first large late-stage clinical trial to further support the amyloid hypothesis.
Jeff D. Williamson, MD, MHS: SPRINT-MIND Trial Preliminary Results
The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.
Krista Lanctot, PhD: Nabilone Significantly Improves Agitation in Alzheimer Disease
The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.
Clive Ballard, MD: Pimavanserin In Patients With Dementia-Related Psychosis
Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.
Alzheimer's Association Develops First Practice Guidelines for Clinical Evaluation of Alzheimer Disease, Other Dementias
The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.
Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease
Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.
James Hendrix, PhD: First Practice Guidelines for Clinical Evaluation of Alzheimer Disease Released
These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.
Galcanezumab Shows Efficacy in Cluster Headache, Migraine
Phase III results have shown galcanezumab is efficacious for multiple headache conditions.
Eptinezumab Reduces Monthly Migraine Days Post-Third, Fourth Infusions
The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.
Rimegepant Eases Pain, Resolves Symptoms for Acute Migraine
Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.
Quarterly Infusions of Eptinezumab Highly Effective for Migraine Prevention in PROMISE 2
The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.
Hideki Garren, MD, PhD: Past and Future Ocrelizumab Analyses
The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).
Vagus Nerve Stimulation Improves Headache, Migraine Pain
A non-invasive vagus nerve stimulation therapy significantly improved pain-free rates compared with a sham device for patients with episodic cluster headache and migraines.
Teriflunomide Improves Patient Satisfaction in Teri-PRO, TENERE Trials
The disease-modifying therapy showed significant improvements in 4 TSQM measures for patients with relapsing multiple sclerosis.
Lilyana Amezcua, MD: Better Understanding MS in the Hispanic Community
The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.
Gregory Day, MD, MSc: The Challenge of Alzheimer Diagnosis
The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.
NP001 Fails to Meet Primary, Secondary Endpoints in ALS Trial
The announcement was discouraging to many, as only 2 agents for ALS have been granted FDA approval in as many decades.
Alberto Espay, MD, MSc: Modifying Thought About Parkinson Disease
The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.
Ralph Kern, MD, MHSc: The State of Therapies for ALS
The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.
Eptinezumab Migraine Prevention Sustained in 12-Month Analysis
More than two-thirds of patients treated with intravenous infusions of the CGRP inhibitor eptinezumab had an average 50% reduction in migraines.
IncobotulinumtoxinA Successful in Treating Sialorrhea in Parkinson, Other Neurological Conditions
Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.
Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis
The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.
Erenumab Displays Success in Patients Who Failed 2 or More Preventative Migraine Treatments
The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.
2 Clarke Drive Cranbury, NJ 08512